2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Chandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055. DOI: 10.1182/blood-2019-128888.Peer-Reviewed Original ResearchAutologous stem cell transplantationAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaTime of diagnosisPeripheral blood involvementBone marrow involvementStem cell transplantationMedian progression-free survivalOverall survivalCell lymphomaBlood involvementFirst remissionMarrow involvementPrognostic factorsCell transplantationFlow cytometryPeripheral bloodWorse outcomesPositive groupNegative groupExtranodal natural killer T-cell lymphomaBone marrowFront autologous stem cell transplantationNatural killer T-cell lymphoma
2013
Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience
Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience. Blood 2013, 122: 5092. DOI: 10.1182/blood.v122.21.5092.5092.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaCutaneous gamma-delta T-cell lymphomaHepatosplenic T-cell lymphomaPeripheral T-cell lymphomaStem cell transplantationInitial therapyCell transplantationLymphoid neoplasmsPrimary cutaneous gamma-delta T-cell lymphomaGamma delta T-cell receptorInitiation of chemotherapySingle-center experienceAggressive clinical courseOff-label useT-cell NHLT cell receptorAdvisory CommitteeAcute GVHDAlloBMT patientsMedian followSalvage therapyAdditional therapyB symptomsFirst remission
2009
Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience
Lansigan F, Cooper D, Seropian S, Foss F. Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience. Journal Of Clinical Oncology 2009, 27: 8558-8558. DOI: 10.1200/jco.2009.27.15_suppl.8558.Peer-Reviewed Original ResearchAggressive T-cell lymphomaProgression-free survivalT-cell lymphomaAuto groupFirst remissionBetter progression-free survivalAggressive B-cell lymphomasMedian prior therapiesNon-relapse mortalitySingle institution experienceRole of transplantationNon-Hodgkin lymphomaLarge cell transformationB-cell lymphomaAllo transplantPrior therapyRelapse mortalityRelapsed diseaseALLO groupPoor OSAllogeneic transplantationLymphoblastic lymphomaMedian ageMedian timeWorse prognosis
2008
A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience
Lansigan F, Seropian S, Cooper D, Foss F. A Retrospective Comparison of Autologous Vs. Allogeneic Transplantation for Peripheral T-Cell Lymphoma: A Single Institution Experience. Blood 2008, 112: 4392. DOI: 10.1182/blood.v112.11.4392.4392.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaAngioimmunoblastic T-cell lymphomaT-cell lymphomaAlloSCT groupNon-Hodgkin lymphomaFirst remissionComplete remissionPartial remissionDonor transplantsAggressive peripheral T-cell lymphomaRefractory cutaneous T-cell lymphomaSurvival rateMatched-unrelated donor transplantProgression-free survival ratesTransplant-related mortality rateAllogeneic stem cell transplantationHepatosplenic T-cell lymphomaPanniculitic T-cell lymphomaAnaplastic large cell lymphomaFirst complete remissionNon-relapse mortalityReduced-intensity transplantsSecond complete remissionOverall survival rateShould All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission?
Alpdogan O, Lenox R, Barile A, Foss F, Shlomchik W, Reuben C, Cooper D, Seropian S. Should All Patients with Acute Myelogenous Leukemia (AML) Other Than Good Risk Cytogenetics Receive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in First Remission? Blood 2008, 112: 4396. DOI: 10.1182/blood.v112.11.4396.4396.Peer-Reviewed Original ResearchAllogeneic HSCTUnrelated donorsTransplant related mortalityEffective curative therapyPoor prognostic featuresConditioning protocolFirst remissionElderly patientsSecondary AMLStandard therapySupportive careCurative therapyMedian ageRelated donorsPrognostic featuresAdvanced ageDonor selectionRelated mortalityRI groupMyeloproliferative diseasePatientsIntensity protocolAMLHSCTTherapy